The Evolving Role of Surgery for Advanced Renal Cell Carcinoma in the Era of Molecular Targeted Therapy

Flanigan, 2001, Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer, N Engl J Med, 345, 1655, 10.1056/NEJMoa003013 Mickisch, 2001, Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial, Lancet, 358, 966, 10.1016/S0140-6736(01)06103-7 Flanigan, 2004, Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis, J Urol, 171, 1071, 10.1097/01.ju.0000110610.61545.ae Escudier, 2005, Randomized Phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC), Proc Am Soc Clin Oncol, 23, 4510, 10.1200/jco.2005.23.16_suppl.lba4510 Motzer, 2006, Sunitinib in patients with metastatic renal cell carcinoma, JAMA, 295, 2516, 10.1001/jama.295.21.2516 Bukowski, 2001, Cytokine therapy for metastatic renal cell carcinoma, Semin Urol Oncol, 19, 148 Wagner, 1999, Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place, J Urol, 162, 43, 10.1097/00005392-199907000-00011 Gnarra, 1994, Mutations of the VHL tumour suppressor gene in renal carcinoma, Nat Genet, 7, 85, 10.1038/ng0594-85 Herman, 1994, Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma, Proc Natl Acad Sci U S A, 91, 9700, 10.1073/pnas.91.21.9700 Gnarra, 1995, Genetics of renal-cell carcinoma and evidence for a critical role for von Hippel-Lindau in renal tumorigenesis, Semin Oncol, 22, 3 Hansen, 2002, Diverse effects of mutations in exon II of the von Hippel-Lindau (VHL) tumor suppressor gene on the interaction of pVHL with the cytosolic chaperonin and pVHL-dependent ubiquitin ligase activity, Molec Cell Biol, 22, 1947, 10.1128/MCB.22.6.1947-1960.2002 Wilhelm, 2004, BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis, Cancer Res, 64, 7099, 10.1158/0008-5472.CAN-04-1443 Ratain, 2006, Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma, J Clin Oncol, 24, 2505, 10.1200/JCO.2005.03.6723 Sun, 2003, J Med Chem, 46, 1116, 10.1021/jm0204183 Mendel, 2003, In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship, Clin Cancer Res, 9, 327 Motzer, 2006, Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma, J Clin Oncol, 24, 16, 10.1200/JCO.2005.02.2574 Gabrilovich, 1998, Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo, Blood, 92, 4150, 10.1182/blood.V92.11.4150 Gabrilovich, 1996, Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells, Nat Med, 2, 1096, 10.1038/nm1096-1096 Gabrilovich, 1999, Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function, Clin Cancer Res, 5, 2963 Gatenby, 2002, The possible role of postoperative azotemia in enhanced survival of patients with metastatic renal cancer after cytoreductive nephrectomy, Cancer Res, 62, 5218 Alexander, 1993, T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors, Cancer Res, 53, 1380 Seliger, 1996, Analysis of the major histocompatibility complex class I antigen presentation machinery in normal and malignant renal cells: evidence for deficiencies associated with transformation and progression, Cancer Res, 56, 1756 Kallfelz, 1999, Induction of immunogenicity of a human renal-cell carcinoma cell line by TAP1-gene transfer, Int J Cancer, 81, 125, 10.1002/(SICI)1097-0215(19990331)81:1<125::AID-IJC21>3.0.CO;2-2 Lahn, 1999, Pro-inflammatory and T cell inhibitory cytokines are secreted at high levels in tumor cell cultures of human renal cell carcinoma, Eur Urol, 35, 70, 10.1159/000019821 Rayman, 2004, Effect of renal cell carcinomas on the development of type 1 T-cell responses, Clin Cancer Res, 10, 6360S, 10.1158/1078-0432.CCR-050011 Wang, 1995, Selective cytokine gene expression in renal cell carcinoma tumor cells and tumor-infiltrating lymphocytes, Int J Cancer, 61, 780, 10.1002/ijc.2910610607 Kolenko, 1999, Dead or dying: necrosis versus apoptosis in caspase-deficient human renal cell carcinoma, Cancer Res, 59, 2838 Cardi, 1998, Expression of Fas(APO-1/CD95) in tumor-infiltrating and peripheral blood lymphocytes in patients with renal cell carcinoma, Cancer Res, 58, 2078 Wu, 2000, Enhancement of Fas-mediated apoptosis in renal cell carcinoma cells by adriamycin, Cancer Res, 60, 2912 Finke, 2001, Tumor-induced sensitivity to apoptosis in T cells from patients with renal cell carcinoma: role of nuclear factor-kappaB suppression, Clin Cancer Res, suppl., 7, 940s Uzzo, 1999, Mechanisms of apoptosis in T cells from patients with renal cell carcinoma, Clin Cancer Res, 5, 1219 Tatsumi, 2003, Disease stage variation in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma, Cancer Res, 63, 4481 Tatsumi, 2002, Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma, J Exp Med, 196, 619, 10.1084/jem.20012142 Belldegrun, 2000, Expanding the indications for surgery and adjuvant interleukin-2-based immunotherapy in patients with advanced renal cell carcinoma, Cancer J Sci Am, suppl., 6, S88 Fujikawa, 2000, Serum immunosuppressive acidic protein and natural killer cell activity in patients with metastatic renal cell carcinoma before and after nephrectomy, J Urol, 164, 673, 10.1016/S0022-5347(05)67278-3 Fujikawa, 1999, Serum C-reactive protein level and the impact of cytoreductive surgery in patients with metastatic renal cell carcinoma, J Urol, 162, 1934, 10.1016/S0022-5347(05)68072-X Dadian, 1994, Immunological parameters in peripheral blood of patients with renal cell carcinoma before and after nephrectomy, Br J Urol, 74, 15, 10.1111/j.1464-410X.1994.tb16538.x Dosquet, 1997, Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma?, Clin Cancer Res, 3, 2451 Edgren, 1999, Serum concentrations of VEGF and b-FGF in renal cell, prostate and urinary bladder carcinomas, Anticancer Res, 19, 869 Sato, 1999, Increased serum levels of vascular endothelial growth factor in patients with renal cell carcinoma, Jpn J Cancer Res, 90, 874, 10.1111/j.1349-7006.1999.tb00829.x Jacobsen, 2000, Vascular endothelial growth factor as prognostic factor in renal cell carcinoma, J Urol, 163, 343, 10.1016/S0022-5347(05)68049-4 Slaton, 2001, Expression levels of genes that regulate metastasis and angiogenesis correlate with advanced pathological stage of renal cell carcinoma, Am J Pathol, 158, 735, 10.1016/S0002-9440(10)64016-3 Yagasaki, 2003, Histopathological analysis of angiogenic factors in renal cell carcinoma, Int J Urol, 10, 220, 10.1046/j.0919-8172.2003.00608.x Feldman, 2002, Prospective analysis of circulating endostatin levels in patients with renal cell carcinoma, Cancer, 95, 1637, 10.1002/cncr.10845 Kattan, 2001, A postoperative prognostic nomogram for renal cell carcinoma, J Urol, 166, 63, 10.1016/S0022-5347(05)66077-6 Leibovich, 2003, Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials, Cancer, 97, 1663, 10.1002/cncr.11234 Motzer, 2004, Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma, J Clin Oncol, 22, 454, 10.1200/JCO.2004.06.132 Patard, 2004, Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study, J Clin Oncol, 22, 3316, 10.1200/JCO.2004.09.104 Kim, 1992, Surgical resection following interleukin 2 therapy for metastatic renal cell carcinoma prolongs remission, Arch Surg, 127, 1343, 10.1001/archsurg.1992.01420110091018 Sherry, 1992, Surgical resection of metastatic renal cell carcinoma and melanoma after response to interleukin-2-based immunotherapy, Cancer, 69, 1850, 10.1002/1097-0142(19920401)69:7<1850::AID-CNCR2820690729>3.0.CO;2-I